Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

AstraZeneca's Farxiga cuts kidney disease risks by 39% in trial that could 'rewrite' the treatment textbook

fiercepharmaSeptember 01, 2020

Tag: AstraZeneca , Farxiga , treatment textbook

PharmaSources Customer Service